EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Steven Rowe, MD
University of Alabama at Birmingham, USA
Principal Investigator - Stuart Elborn, MD
Royal Brompton Hospital, London UK
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
75 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hôpital Erasme
Brussels, Belgium
- Uz Leuven
Leuven, Belgium
- University of Calgary
Calgary, Alberta, Canada
- Ottawa Hospital
Ottawa, Ontario, Canada
- St. Michael'S Hospital
Toronto, Ontario, Canada
- Centre Hospitalier de Dunkerque
Dunkirk, France
- Hôpital Albert Michallon
Grenoble, France
- Hopital Arnaud de Villeneuve
Montpellier, France
- Hôpital Cochin
Paris, France
- Ch Lyon Sud
Pierre-Bénite, France
- Charite' University
Berlin, Germany
- Krankenhaus Donaustauf
Donaustauf, Germany
- Carl-Gustav-Klinikum Dresden, Mukoviszidose Centrum "christiane Herzog"
Dresden, Germany
- Ruhrlandklinik Essen
Essen, Germany
- Institut Für Klinische Forschung Pneumologie
Frankfurt, Germany
- Klinikum Der Johann Wolfgang Goethe-Universität
Frankfurt, Germany
- Medizinische Hochschule Hannover
Hanover, Germany
- Universitätsklinikum Jena Cf Centre
Jena, Germany
- Lungenärztliche Praxis München-Pasing
München-Pasing, Germany
- Klinikum Stuttgart Cf Ambulanz
Stuttgart, Germany
- Ospedali Riuniti Di Ancona
Ancona, Italy
- Azienda Ospedaliero Universitaria
Catania, Italy
- Azienda Ospedaliera A Meyer
Florence, Italy
- Irccs Ospedale Pediatrico Bambino
Rome, Italy
- Ospedale Civile Maggiore
Verona, Italy
- Belfast City Hospital
Belfast, United Kingdom
- Bristol Royal Infirmary
Bristol, United Kingdom
- Llandough Hospital
Cardiff, United Kingdom
- St James'S University Hospital
Leeds, United Kingdom
- Liverpool Heart and Chest Hospital
Liverpool, United Kingdom
- King'S College Hospital
London, United Kingdom
- Royal Brompton Hospital
London, United Kingdom
- University Hospital of South Manchester
Manchester, United Kingdom
- Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom
- University Hospital Southampton
Southampton, United Kingdom
- Royal Stoke University Hospital
Stoke-on-Trent, United Kingdom
- University of Alabama
Birmingham, Alabama, United States
- Providence Health and Services
Anchorage, Alaska, United States
- Banner University of Arizona Medical Center
Tucson, Arizona, United States
- Childrens Hospital Los Angeles
Los Angeles, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Oct 2015
- Primary completion
- 20 Apr 2018
- Completion
- 16 May 2018
- Last update posted
- 4 Sept 2019
- Registered enrollment
- 200
- Registry id
- NCT02443688
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.